We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

May 13, 2022

Sprint: DTx - Pharma Partnerships: Where Are We Heading To?

Commentary
HealthXL Team & HealthXL Community
&

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint we discussed the current state of DTx-Pharma partnerships and what the future looks like. In this blog we’ve pulled out the top takeaways from this series. 

5 Key Recommendations: 

Digital Therapeutic (DTx) companions are a clear route for DTx-Pharma partnerships to begin: Partnerships between DTx companies and pharma may initially focus on DTx companions because they will generate evidence for the real world use to feed back into the drug discovery phase. DTx companies should recognise where they can add value to a pharmaceutical product or franchise. The position that pharma takes may depend on whether the DTx can support their go-to-market strategy or if it is a competitor. Pharma may have more appetite for companion type platforms that would help support their therapeutic areas and pharmaceuticals. A DTx solution that can help capture patient data, potentially reinforce the use and continuous prescribing of the pharmaceutical, and offer post treatment monitoring for drug reactivation may fit better into the current ecosystem. However, whilst a companion is a clear and obvious route, there’s value to both standalone and combination DTx products. For pharma, DTx partnerships can be a strategic way to diversify their portfolios.

Clinical evidence should go hand-in-hand with any Pharma-DTx partnership strategy: Clinical evidence is the nature of pharma business. DTx companies need to have more competencies to provide valid clinical evidence and be open to speaking the language of clinical trials and clinical outcomes if they are looking to engage with pharma. If necessary, some pharma companies  may support DTx companies in gaining evidence if they have the courage to try to create it and fail. Clinical evidence is only going to become more important as the market becomes more saturated. Digital products improve dynamically after they reach the market, providing an opportunity to collect real world evidence to support updates and product improvements across its lifespan. This reinforces the importance of DTx companies having competencies in discussing clinical evidence. 

Seek a mentor to navigate the pharma organization: DTx companies have insight into the concept of a digital relationship to people with disease. This insight is underrepresented to some of the stakeholders in pharma. Day-to-day budget holders and decision makers in organizations may be separate from the conversation or may not always be able to see the long term value proposition of DTx, even if there’s senior management support. This brings up challenges for accessing the right gateway within the organization. There is an opportunity for DTx companies to seek a mentor as an executive sponsor and digital health advocate to help navigate the organization.

Adoption of a DTx by the Healthcare Providers (HCPs) is important: Engaging HCPs needs to be strongly prioritized if the parma-DTx partnership is to be successful. Whether the DTx route to market is direct to consumer (D2C) or via a Provider, and even if the DTx is reimbursed and has a framework prepared, there needs to be a strategy in place to encourage  HCPs to change their habits before they prescribe, recommend or use the DTx. A balance between cost and revenue of the DTx might be agreed upon at pharma management level. However, this does not always prove resilient when attempting to get HCPs to adopt the solution. Simplistically, in order to engage HCPs, a minimal friction environment platform must be created and clinical outcomes from the DTx should be available in the HCP’s electronic health record (EHR). However, HCPs are only one of the key stakeholders. Engagement of patients and users will also be a key component of success.

Timing is everything: Pharma companies are still at an early stage in their understanding of DTx, but are reticent about the use of DTx upstream in the development cycle. Digital health teams in pharma are asked to bring in DTx much later in the process, but it is not enough to approach DTx as a case finding tool when drug exclusivity runs out. Pharma teams on the commercial side and teams on the clinical trials side need to engage more to get DTx incorporated earlier in the pharmaceutical stage to span R&D, clinical trials and commercial thinking. 

Future Gazing

DTx-Pharma partnerships are nascent and the strategy is only starting to become well defined. These partnerships need to be more patient-focused and business oriented. The patient's needs must always come first and the ideal partnership will drive better outcomes by promoting the intervention without negatively affecting drug sales.

DTx platforms need to be interoperable and easy to use. Rather than numerous point solutions, HCPs need a simple solution that fits into their current workflow. Solutions that address common comorbidities may be easier to adopt and more likely to gain tracking with HCPs.  If this approach fails in the short-term, platforms that address general symptoms across multiple therapeutic areas may find more success with HCPs. 

Experts included:  Bernhard Kappe (Founder & CEO, Orthogonal), Daphne Petrich (Senior Business Development Manager, HelloBetter), Deepti Warad (Senior Clinical Trial Physician, BMS), Joseph Rubinsztain (CEO, ChronWell), Karine Soulat (Marketing Consultant on health and ehealth, Ke-Health), Katie Cannon (Head of Growth, Avegen), Kevin Darcy (Director, Link Strategy, Veeva Systems), Laura Carlin (Head of Strategic Alliances, ieso), Matt Norton (VP of Marketing & Commercial Development, S3 Connected Health) Michael Heupel (Head of Pharma & MedTech, Flying Health), Omri Shor (Founder & CEO, Medisafe), Quake Pletcher (Sr. Director, Digital Health Partnership Management, Eli Lilly and Company), Vasyl Pyrozhyk (VP Healthcare, Sumitomo Mitsui Banking Corporation), and Aislinn Mc Phillips (Digital Health Analyst, HealthXL).

*All opinions are the participants’ own and do not necessarily reflect the stance of their respective employers.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Standing Out from the Crowd in Economic Recession

14th February @ 10:45AM EDT

The digital health industry has seen a decline in funding in recent times, as investors have become more knowledgeable and selective to where they allocate their capital. Seats are limited so apply now to secure your place.

Featuring
Jeremy Sohn
Jeremy Sohn
Managing General Partner, P74 Ventures
Featuring
Jeremy Sohn
Jeremy Sohn
Managing General Partner, P74 Ventures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Endpoints and Control Arms in Trials for DTx

15th February @ 10:45AM EDT

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

The Role of the Consumer Experience in DTx

15th February @ 10:45AM EDT

As technology advances in all sectors (e.g. fintech, entertainment, etc), consumer behaviour changes and the expectations on user experience are higher than before. Apply now to secure your place in this meeting where you will dive deeper into this topic with your peers.

Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Incorporating Extended Reality (XR) in Physician's’ Daily Work

28th February @ 10:45AM EDT

The healthcare industry is undergoing a digital transformation and extended reality (XR) technologies such as virtual reality (VR) and augmented reality (AR) are expected to play a significant role in this change in the next few years. Apply now to join this Masterclass led by Nemanja Kovačev, MedTech Expert at HTEC Group.

Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group
Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Health Meeting
7th February @ 10:45AM EDT

Product Differentiation for Digital Health Solutions in the Cardiometabolic Disease Area

In the past few years, digital health solutions have proven to be helpful in preventing and managing cardiometabolic diseases remotely, leading to better  health outcomes and less hospitalizations, emergency visits, and in-office visits.

Jenn Roberts
Featuring
Jenn Roberts
Vice President Employer Health Strategy, Hello Heart
Telemedicine & Virtual Care Delivery
9th February @ 10:45AM EDT

Business Opportunities for Digital Health in Autoimmune Conditions: Upcoming Blockbuster Drugs

Millions of people worldwide suffer from autoimmune conditions such as rheumatoid arthritis (RA), psoriasis, lupus, Crohn's disease, multiple sclerosis, atopic dermatitis, to name a few. Join this meeting to deep dive into this topic in the Immunology Meeting Series. Seats are limited so apply now to secure your place.

Erik Janssen
Featuring
Erik Janssen
VP Global Digital Care Transformation Immunology, UCB
Digital Therapeutics (DTx)
14th February @ 10:45AM EDT

Masterclass: Standing Out from the Crowd in Economic Recession

The digital health industry has seen a decline in funding in recent times, as investors have become more knowledgeable and selective to where they allocate their capital. Seats are limited so apply now to secure your place.

Jeremy Sohn
Featuring
Jeremy Sohn
Managing General Partner, P74 Ventures
Digital Therapeutics (DTx)
15th February @ 10:45AM EDT

Masterclass: Endpoints and Control Arms in Trials for DTx

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Acacia Parks
Featuring
Acacia Parks
Chief Science Officer, Twill

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.